AI and machine learning: FDA spells out specifics from drug discovery to manufacturing
From drug target identification and early discovery work to postmarket surveillance and advanced manufacturing, the FDA on Wednesday outlined its key recommendations on how to use artificial intelligence and machine learning, two new and key components to drug development that the agency is trying to better understand.
The 31-page discussion paper and website note that the FDA has seen a significant increase in the number of drug and biologic application submissions using AI/ML components over the past few years, with more than 100 submissions reported in 2021.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters